S20-525 Platform for peptide vaccine sequence optimization Stanford researchers have developed methods for optimizing peptide vaccines, with candidate peptides against EGFPvIII-expressing glioblastoma and SARS-CoV-2. Albert Wong
S10-393 Cancer vaccine optimization with EGFRvIII-derived peptide Disease indication - Oncology/solid tumors, notably glioblastoma Drug format - Engineered peptide for cancer vaccine optimization. Drug class - Improvement to existing vaccine. Albert Wong